Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Proliferation of some cultured human tumor cell lines bearing high numbers of epidermal growth factor (EGF) receptors is paradoxically inhibited by EGF in nanomolar concentrations. In the present study, we have investigated the biochemical mechanism of growth inhibition in A431 human squamous carcinoma cells exposed to exogenous EGF. In parallel, we studied a selected subpopulation, A431-F, which is resistant to EGF-mediated growth inhibition. We observed a marked reduction in cyclin-dependent kinase-2 (CDK2) activity when A431 and A431-F cells were cultured with 20 nM EGF for 4 h. After further continuous exposure of A431 cells to EGF, the CDK2 activity remained at a low level and was accompanied by persistent G1 arrest. In contrast, the early reduced CDK2 activity and G1 accumulation in A431-F cells was only transient. We found that, at early time points (4-8 h), EGF induces p21Cip1/WAF1 mRNA and protein expression in both EGF-sensitive A431 cells and EGF-resistant A431-F cells. But only in A431 cells, was p21Cip1/WAF1 expression sustained at a significantly increased level for up to 5 d after addition of EGF. Induction of p21Cip1/WAF1 by EGF could be inhibited by a specific EGF receptor tyrosine kinase inhibitor, tyrphostin AG1478, suggesting that p21Cip1/WAF1 induction was a consequence of receptor tyrosine kinase activation by EGF. We also demonstrated that the increased p21Cip1/WAF1 was associated with both CDK2 and proliferating cell nuclear antigen (PCNA). Taken together, our results demonstrate that p21Cip1/WAF1 is an important mediator of EGF-induced G1 arrest and growth inhibition in A431 cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
Luo, Y., Hurwitz, J., & Massagué, J. (1995) · Nature · doi:10.1038/375159a0 · Cited by 549 · cited 4×
“An amino-terminal domain of the p21 cipl/wAFt molecule inhibits cyclin/CDK kinases and a carboxy-terminal domain inhibits PCNA (Chen et al., 1995; Luo et al., 1995 ).”
BackgroundInfluentialSeparate domains of p21 involved in the inhibition of Cdk kinase and PCNA
Chen, J., Jackson, P. K., Kirschner, M. W., & Dutta, A. (1995) · Nature · doi:10.1038/374386a0 · Cited by 548 · cited 13×
“7 B) was accompanied by a rise and fall in p21Cipl/wgF1 associated PCNA (Fig.”
BackgroundInfluentialFlores-Rozas, H., Kelman, Z., Dean, F. B., Pan, Z. Q., Harper, J. W., Elledge, S. J., O'Donnell, M., & Hurwitz, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8655 · Cited by 416 · cited 4×
“p21 ciplmAFa also binds to proliferating cell nuclear antigen (PCNA) and inhibits in vitro PCNA-dependent DNA replication ( Flores-Rozas et al., 1994; Waga et al., 1994), which p27 KIP1 cannot do (Luo et al., 1995).”
BackgroundInfluential
Cited by
Chin, Y. E., Kitagawa, M., Su, W.-C. S., You, Z.-H., Iwamoto, Y., & Fu, X.-Y. (1996) · Science · doi:10.1126/science.272.5262.719 · Cited by 696
Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E., & McMahon, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5598 · Cited by 639
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
Self-citationBromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7673 · Cited by 422
Decorin Is a Biological Ligand for the Epidermal Growth Factor Receptor
Iozzo, R. V., Moscatello, D. K., McQuillan, D. J., & Eichstetter, I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.4489 · Cited by 382
Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor.
Moscatello, D. K., Santra, M., Mann, D. M., McQuillan, D. J., Wong, A. J., & Iozzo, R. V. (1998) · Journal of Clinical Investigation · doi:10.1172/jci846 · Cited by 272
Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14
“We also showed that both cetuximab and erlotinib inhibit cell cycle progression by causing the G0/G1 phase arrest (Figure 5), which is in line with the previous studies [45,87,88].”
Result
Metadata
- Authors
- Fan, Z., Lu, Y., Wu, X., DeBlasio, A., Koff, A., & Mendelsohn, J.
- Venue
- The Journal of cell biology
- Publisher
- Rockefeller University Press
- Published
- 1995-10-01
- Volume
- 131
- Issue
- 1
- Pages
- 235-242
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2117022243
- Cited by
- 125
- References
- 4
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.